Elanco Q3 2026 Earnings: Pet Health Growth Expands Margins

Elanco Animal Health (NYSE: ELAN) reported Q3 2026 revenue of $1.265 billion, up 11% from $1.137 billion a year earlier, while GAAP diluted EPS improved to $0.04 from a loss of $0.07. Pet Health growth, higher pricing, and favorable product mix expanded margins, although operating cash flow was nearly unchanged. The company raised its 2026 outlook after ending the quarter with net leverage of 2.9x adjusted EBITDA.

Core Financial Results

For the quarter ended September 30, organic constant-currency revenue grew 9%, compared with the 11% reported increase. Elanco’s organic measure excludes foreign-exchange effects, revenue from the April 2026 acquisition of AHV International, and royalty revenue and sales-based milestones previously sold to a third party.

Profitability grew faster than revenue. Adjusted EBITDA increased 23%, adjusted EPS rose 42%, and Elanco moved from a GAAP net loss to positive net income.

Adjusted EBITDA margin is calculated after excluding royalty revenue and sales-based milestones that were sold to a third party.

Business and Segment Performance

Pet Health was the main growth driver, with both reported and organic constant-currency revenue increasing 14%. The segment benefited from a 5% price increase and a 9% volume increase, primarily reflecting demand for Zenrelia, Credelio Quattro, and AdTab.

Farm Animal grew more slowly and showed substantial differences by species. Cattle revenue increased 17% on a reported basis, while poultry declined 7%.

Within Pet Health, the Advantage family generated $115 million and the Seresto family contributed $49 million. Seresto was affected by inventory reductions at U.S. retailers, although Elanco said underlying performance remained in line with its expectations.

Product adoption data supported the growth in newer treatments. Zenrelia added 1,600 U.S. clinics during the quarter, bringing its total to approximately 19,000, while Credelio Quattro added another 1,600 clinics and reached more than 16,500 clinics, or roughly 55% penetration. Credelio Quattro also became Elanco’s largest branded U.S. Pet Health product by revenue.

Contract Manufacturing and Other includes royalties, sales-based milestones, and third-party manufacturing. Sold royalty and milestone revenue still required to be recognized under GAAP was $21 million, up from $6 million, so the category’s reported increase does not represent only underlying manufacturing demand.

Pricing and Mix Lifted Margins Despite Higher Launch Spending

Elanco’s overall price contribution accelerated to 4%, while volume contributed 5%. Higher prices and a favorable mix from U.S. Pet Health and global ruminants helped adjusted gross margin expand 300 basis points to 56.1%. Adjusted gross profit increased to $699 million from $601 million, growing faster than total revenue.

The company continued to spend behind product launches and research. Total operating expenses rose 12% to $492 million, including a 12% increase in marketing, selling, and administrative expenses to $393 million and an 11% increase in R&D expenses to $99 million. Despite that spending, adjusted EBITDA margin increased by 200 basis points because gross profit growth outpaced operating-expense growth.

The return to GAAP profitability was also helped by lower asset impairment, restructuring, and other special charges, which declined to $3 million from $25 million. A lower effective tax rate provided additional support. These benefits were partly offset by reported net interest expense rising by $7 million to $59 million.

Cash Flow and Leverage

Operating cash flow was nearly flat at $216 million, compared with $219 million a year earlier. As a result, the improvement in quarterly net income did not produce a corresponding increase in reported operating cash flow during Q3.

At September 30, Elanco had gross debt of $3.728 billion and cash and cash equivalents of $465 million. Net debt was $3.005 billion, and the net leverage ratio declined to 2.9x trailing adjusted EBITDA, down 0.7x from December 31, 2025. Management said reaching the 2.9x level earlier than anticipated increased the company’s flexibility in allocating capital, without specifying a new transaction or shareholder-return plan.

Financial Guidance

Elanco raised its full-year revenue, adjusted EBITDA, and adjusted EPS ranges. It also increased its organic constant-currency growth expectation to approximately 8% from the previous 6% to 7% range and now expects greater gross-margin expansion.

Full-year revenue guidance excludes royalty revenue and sales-based milestones sold to a third party. The company expects favorable currency movements to add approximately $60 million to reported revenue compared with 2025. It also raised its 2026 innovation revenue target to $1.275 billion.

For Q4 2026, Elanco guided to revenue of $1.190 billion to $1.215 billion, adjusted EBITDA of $185 million to $200 million, and adjusted EPS of $0.16 to $0.19. Organic constant-currency revenue is expected to grow 4% to 6%, while operating expenses are expected to rise approximately 11% in constant currency as the company continues funding product launches and R&D.

Elanco’s early 2027 outlook retained the framework presented at its December 2025 Investor Day: mid-single-digit organic constant-currency revenue growth, high-single-digit adjusted EBITDA growth, and low-double-digit adjusted EPS growth.

Risks Investors Should Monitor

• New-product execution: Pet Health growth depended substantially on Zenrelia, Credelio Quattro, and AdTab. Continued adoption, competitive activity, and the planned European launch of Credelio Quattro in Q1 2027 will affect whether the current trajectory continues.
• Higher operating investment: Launch and R&D spending pushed quarterly operating expenses up 12%, and Elanco expects another approximately 11% constant-currency increase in Q4. Slower revenue growth could make that spending more difficult to absorb.
• Uneven portfolio performance: Cattle and Pet Health grew, but poultry revenue declined 7% and Seresto faced U.S. retailer inventory reductions. Further channel adjustments or weakness in individual species could weigh on consolidated growth.
• Debt and interest costs: Net leverage improved to 2.9x, but Elanco still had $3.728 billion of gross debt, while quarterly reported net interest expense increased to $59 million.
• Currency sensitivity: Approximately $60 million of the expected full-year reported revenue benefit comes from favorable foreign exchange. Changes from the exchange rates used in the guidance could affect reported results even if organic performance is unchanged.

Conclusion

Elanco’s Q3 2026 results combined faster Pet Health growth, increased pricing, and favorable mix to produce meaningful gross-margin and adjusted EBITDA expansion. The company also returned to GAAP profitability and lowered leverage, though operating cash flow remained nearly flat and launch-related spending continued to rise. Execution on newer Pet Health products, the balance between investment and margin gains, and delivery of the raised full-year outlook are the main items to monitor next.